Table 4 Duration of dual antiplatelet therapy during follow-up in ACS and non-ACS patients
Variable | All patients | Non ACS | ACS | p value |
|---|---|---|---|---|
Number of patients | 447 | 334 | 113 | – |
4 weeks aspirin 100 mg + clopidogrel | 267 (59.7 %) | 207 (60.5 %) | 60 (57.1 %) | 0.385 |
3 months aspirin 100 mg + clopidogrel | 5 (1.2 %) | 5 (1.5 %) | 0 (0.0 %) | |
6–12 months aspirin 100 mg + clopidogrel | 68 (15.2 %) | 52 (15.2 %) | 16 (15.2 %) | |
12 months aspirin 100 mg + clopidogrel | 70 (15.7 %) | 47 (13.7 %) | 23 (21.9 %) | |
Aspirin 100 mg + clopidogrel life long | 2 (0.4 %) | 2 (0.6 %) | 0 (0.0 %) | |
12 months aspirin 100 mg + prasugrel | 3 (0.7 %) | 2 (0.6 %) | 1 (1.0 %) | |
12 months aspirin 100 mg + ticagrelor | 3 (0.7 %) | 2 (0.6 %) | 1 (1.0 %) | |
Unknown | 29 (6.5 %) | 24 (7.0 %) | 5 (4.8 %) |